An investigation was announced over potential securities laws violations by Legend Biotech Corporation in connection with certain financial statements.

Investors who purchased shares of Legend Biotech Corporation (NASDAQ: LEGN), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on whether a series of statements by Legend Biotech Corporation regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Somerset, NJ based Legend Biotech Corporation, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel cell therapies for oncology and other indications. Legend Biotech Corporation reported that its annual Total Revenue rose from 489.79 million in 2021 to $117 million in 2022, and that its Net Loss increased from $386.2 million in 2021 to $446.34 million in 2022.

On November 28, 2023, the U.S. Food and Drug Administration ("FDA") announced that it "is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action" after "receiving reports of T-cell malignancies, including chimeric antigen receptor CAR-positive lymphoma, in patients who received treatment with BCMA- or CD19-directed autologous CAR T cell immunotherapies." The FDA's press release listed Legend's Carvykti (ciltacabtagene autoleucel) as among the approved products in the class of products at issue.

Shares of Legend Biotech Corporation (NASDAQ: LEGN) declined from $77.32 per share in July 2023, to as low as $57.24 per share on November 28, 2023.

Those who purchased shares of Legend Biotech Corporation (NASDAQ: LEGN) have certain options and should contact the Shareholders Foundation.

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com